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Objective: To determine the relationship between lifelong exercise dose and the prevalence 
of cardiovascular morbidity. 
Patients and Methods: Between June 2011 and December 2014, 21,266 individuals 
completed an online questionnaire regarding their lifelong exercise patterns and 
cardiovascular health status. Cardiovascular disease (CVD) was defined as a diagnosis of 
myocardial infarction, stroke or heart failure, whereas cardiovascular risk factors (CVRF) 
were defined as hypertension, hypercholesterolemia, and type 2 diabetes. Lifelong exercise 
patterns were measured over a median of 32 years for 405 CVD cases, 1,379 CVRF cases, 
and 10,656 controls. Participants were categorized into non-exercisers and quintiles (Q1 to 
Q5) of exercise dose (MET-min/week). 
Results: CVD/CVRF prevalence was lower for each exercise quintile compared to non-
exercisers (CVD: non-exercisers: 9.6% vs. Q1: 4.4%, Q2: 2.8%, Q3: 2.4%, Q4: 3.6%, Q5: 
3.9%; P<.001; CVRF non-exercisers: 24.6% vs. Q1: 13.8%, Q2: 10.2%, Q3: 9.0%, Q4: 9.4%, 
Q5: 12.0%; P<.001). The lowest exercise dose (Q1) significantly reduced CVD and CVRF 
prevalence, but the largest reductions were found at a dose of 764-1,091 MET-min/week for 
CVD (ORadjusted: 0.31 [95%CI: 0.20-0.48]) and CVRF (ORadjusted: 0.36 [95%CI: 0.28-0.47]). 
CVD/CVRF prevalence did not further decrease among higher exercise dose groups. Exercise 
intensity did not influence the relationship between exercise patterns and CVD or CVRF.  
Conclusion: Our findings demonstrate a curvilinear relationship between lifelong exercise 
patterns and cardiovascular morbidity. Low exercise doses can effectively reduce CVD/CVRF 
prevalence, but engagement of exercise for 764 to 1,091 MET-min/week is associated with 
the lowest CVD/CVRF prevalence. Higher exercise doses do not yield additional benefits.  
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Physical inactivity is considered a major modifiable risk factor for all-cause mortality 1, 2, 
whereas habitual physical exercise reduces the risk of cardiovascular morbidity and mortality 
3, 4. Regular exercise is also associated with increased survival in the general and the athletic 
population 5-7. Therefore, the World Health Organization and Centers for Disease Control and 
Prevention recommend adults to engage in at least 150 minutes of moderate-intensity exercise 
or 75 minutes of vigorous-intensity exercise per week for optimal cardiovascular and global 
health 8-10. These guidelines also state that there is even more benefit from 300 minutes per 
week of moderate, and 150 minutes of vigorous-intensity exercise.  
Such recommendations suggest increasing benefit with increasing exercise dose, but 
recent studies suggest a potential U-shaped association, indicating that high doses of exercise 
may abolish the beneficial health effects 11, 12. Results of the Copenhagen Heart Study 
indicate that vigorous joggers have similar mortality rates as the sedentary non-joggers 
(hazard ratio: 1.97, 95% CI: 0.48-8.14 and hazard ratio: 0.66, 95% CI: 0.32-1.38, 
respectively) 11. The Million Women Study indicates that daily strenuous activities increase the 
risk for stroke and venous thromboembolism compared to strenuous activities performed for 
2-3 sessions/week 12. The notion that exercise might increase the risk for cardiovascular 
morbidity is striking, but strong evidence is currently lacking.  
To confirm or reject the U-shaped association between exercise and cardiovascular 
morbidity, this study aimed to determine the relationship between lifelong exercise dose and 
the prevalence of cardiovascular morbidity (myocardial infarction, stroke, and heart failure) in 
a physically active population. We collected data in 21,266 participants of the Nijmegen 
Exercise Study (Nijmegen, the Netherlands) and hypothesized that high lifelong exercise 
doses relate to a decrease in the prevalence of cardiovascular morbidity. 




Study design and study population 
The Nijmegen Exercise Study is a population-based study among participants of Dutch sport 
events and their family members and friends. The study is designed to examine the impact of 
a physically active lifestyle on health, quality of life, and the development and progression of 
cardiovascular disease (CVD). Participants of the International Nijmegen Four Days 
Marches, the largest multi-day walking event in the world, and participants of the Seven Hills 
Run, one of the largest road races in the Netherlands, were eligible to participate in the 
Nijmegen Exercise Study. Furthermore, family members and friends of the participants of 
both Dutch sport events were also eligible for participation. Between June 2011 and 
December 2014, inactive and active participants were recruited via newsletters and internet 
advertisements. Participants completed an online questionnaire about demographic 
characteristics, anthropometric measures, lifestyle factors, lifelong exercise patterns, 
cardiovascular health status, and family history of CVD. To assess the impact of lifelong 
physical exercise patterns on cardiac morbidity, participants with an age ≥35 years were 
included in the present study. The study adhered to the Declaration of Helsinki. The Local 
Committee on Research Involving Human Subjects of the region Arnhem and Nijmegen 
approved the study and all participants gave their written informed consent. 
 
Lifestyle factors 
Participants were asked about their smoking status (never, former, or current) and the highest 
level of education they completed. Level of education was categorized by low (elementary 
school or basic vocational education), intermediate (secondary vocational education), or 
high/academic (higher professional education or academic education). 
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History of cardiovascular diseases 
Participants were asked whether (yes/no) and when (age) their physician diagnosed CVD 
(myocardial infarction, stroke, or heart failure) or presence of cardiovascular risk factors 
(CVRF) (hypertension, hypercholesterolemia, or diabetes [type 2]). All participants were also 
queried about their (cardiovascular) medication usage. To validate CVD/CVRF diagnosis, we 
performed a cross-check with medication usage. Participants with CVD or CVRF, who did 
not report cardiac medication usage were excluded from the study. Participants were allocated 
to the control group if they had no cardiac medical history and did not use cardiac medication. 
When both CVD and CVRF were diagnosed, the participant was allocated to the CVD group. 
Participants with congenital heart disease, defined as diagnosis of CVD before the age of 35 
years, were excluded from further analysis (Figure 1). Participants were also asked whether 
CVD was present in their immediate biological family (defined as the participant’s parents, 
brothers, and sisters).  
 
Lifelong exercise patterns 
The lifelong exercise patterns before the age of CVD/CVRF diagnosis (cases) or age at study 
participation (controls) were evaluated via an exercise history questionnaire, distinguishing 
four age-periods: I) 18-29 years, II) 30-49 years, III) 50-64 years, and IV) ≥65 years. Within 
these categories, participants were asked per period whether (yes/no) they performed exercise 
with the corresponding (1) exercise time (hours) per week and (2) self-perceived intensity 
(light / moderate / vigorous). Participants who failed to complete the exercise questionnaire 
were excluded from the final analysis. Based on Ainsworth’s compendium of physical 
activities 13, we assigned a metabolic equivalent of task (MET) value of 2.5 for light, 4.5 for 
moderate, and 8.5 for vigorous exercise. MET minutes (MET-min) were calculated by 
multiplying the exercise time in minutes with the accompanying MET score of the self-
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perceived intensity 13. The average weekly amount of lifelong exercise (MET-min/week) was 
calculated between the age of 18 and the age of CVD/CVRF diagnosis for the cases. 
Calculations were made for control participants between the age of 18 and age at study 
participation. Participants were classified into 6 groups: non-exercisers and quintiles of 
weekly exercise dose (MET-min/week).  
 
Data analysis 
The characteristics of non-exercisers and exercisers were summarized with means and 
standard deviations, or counts and proportions. CVD and CVRF prevalence were determined 
for each exercise dose quintile. Logistic regression was used to calculate the odds ratios (OR) 
of CVD with non-exercisers set as the reference category. In the logistic regression analysis, 
we adjusted for the following potential confounders: age at CVD/CVRF diagnosis (cases) or 
age of study participation (controls), sex, smoking status, level of education, and CVD family 
history. To determine the impact of intensity on CVD and CVRF prevalence across exercise 
dose quintiles, the proportion of light, moderate, and vigorous intensity were calculated per 
exercise dose quintile. The analysis was performed via a two-way analysis of variance, with 
factors 1) CVD/CVRF (yes/no) and 2) exercise dose quintiles. All statistical analyses were 
performed using SPSS 21.0 software (IBM Corp. Released 2012. IBM SPSS Statistics for 





21,266 participants completed the online questionnaire. After the exclusion of participants 
with cardiovascular risk factors and missing data, 12,440 participants were available for 
Maessen et al. 
8 
 
analysis (Figure 1). We calculated the average weekly lifelong exercise dose over a median 
period of 32 [interquartile range Q25–Q75: 26–39] years for 405 CVD cases, 1,379 CVRF 
cases, and 10,656 controls. The CVD sample most frequently had a myocardial infarction 
(51%), followed by heart failure (30%) and stroke (19%) (Table 1). The CVRF sample most 
frequently had hypertension (72%), followed by hypercholesterolemia (24%) and diabetes 
(4%) (Table 2). In general, exercisers had a 58% lower risk to develop CVD (adjusted OR: 
0.42 (95% CI: 0.29-0.60) and a 56% lower risk to develop CVRF (adjusted OR: 0.44 [95% 
CI: 0.35-0.55]) compared to the non-exercisers. These associations were consistent regardless 
of sex, age, smoking status, family history, and level of education (Figure 2).  
 
(Table 1 here). 
(Table 2 here). 
 
Exercise dose 
Compared to non-exercisers, CVD prevalence was lower in all exercise dose quintiles (non-
exercisers: 9.6% vs. Q1: 4.4%, Q2: 2.8%, Q3: 2.4%, Q4: 3.6%, Q5: 3.9%; P<.001). After 
adjustment for age, sex, smoking status, level of education, and CVD family history, the 
adjusted OR of CVD prevalence to lifelong exercise dose were for Q1) 0.55 [95% CI: 0.36-
0.82], Q2) 0.38 [95% CI: 0.25-0.59], Q3) 0.31 [95% CI: 0.20-0.48], Q4) 0.41 [95% CI: 0.27-
0.62], and Q5) 0.43 [95% CI: 0.28-0.65] (Figure 3a). Participants who exercised at a dose of 
773 to 1,091 MET-min/week (Q3) reported the lowest CVD prevalence, with a risk reduction 
of 69% compared to the non-exercisers. An exercise dose of 773-1,091 MET-min is equal to a 
weekly run of 13 to 18 km at a speed of ~8.0 km/h or a weekly walk of 17 to 24 km at a speed 
of ~5.6 km/h. 
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CVRF prevalence was also lower in all exercise dose quintiles (non-exercisers: 24.6% 
vs. Q1: 13.8%, Q2: 10.2%, Q3: 9.0%, Q4: 9.4%, Q5: 12.0%; P<.001). After adjustment for 
age, sex, smoking status, level of education, and CVD family history, the adjusted OR of 
CVRF prevalence to lifelong exercise dose were for Q1) 0.57 [95% CI: 0.44-0.72], Q2) 0.43 
[95% CI: 0.33-0.55], Q3) 0.36 [95% CI: 0.28-0.47], Q4) 0.36 [95% CI: 0.28-0.47], and Q5) 
0.47 [95% CI: 0.37-0.60] (Figure 3b). Participants who exercised at a dose of 764 to 1,085 
MET-min/week (Q3) reported the lowest CVRF prevalence, with a risk reduction of 64% 
compared to the non-exercisers.  
 
Exercise intensity 
In general, CVD, CVRF, and control participants exercised mostly at a moderate intensity 
(71%), followed by vigorous intensity (16%) and light intensity (13%). The proportion of 
light and moderate intensity exercise decreased with higher exercise dose quintiles (P<.001), 
whereas the proportion of vigorous intensity exercise increased with higher exercise dose 
quintiles (P<.001). CVD and CVRF participants performed more light intensity exercise 
compared to controls across quintiles (CVD: Pinteraction=0.028; CVRF Pinteraction=0.001). 
Proportions of moderate intensity exercise (CVD: P=.48; CVRF: 0.17) and vigorous intensity 
exercise (CVD: P=.20; CVRF: 0.36) did not differ between CVD/CVRF and controls 
participants across quintiles (Figure 4).  
 
DISCUSSION 
This study presents several major findings. First, exercise below the recommended dose is 
associated with reduced cardiovascular morbidity. Second, performing exercise at a dose of 
764 to 1,091 MET-min per week is associated with the lowest reduction in CVD/CVRF 
prevalence, approximating 69% for CVD and 64% for CVRF. Third, a higher exercise dose 
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does not yield additional cardiovascular benefits, as we observed that CVD and CVRF 
prevalence did not further decrease among the highest exercise dose groups. Fourth, these 
data do not support the presence of the U-shaped association between exercise and CVD 
prevalence, but reinforce the hypothesis that regular exercise performance is a potent lifestyle 
intervention to reduce cardiovascular burden.  
 
Several studies reported the favourable health effects of exercise 7, 14-16, as evidenced by 
reductions in mortality risk in physically active individuals. The present study focused on 
cardiovascular morbidity only, and demonstrated a reduced CVD and CVRF prevalence 
across all exercise quintiles. Current exercise guidelines recommended a (minimum) weekly 
exercise dose of 675 MET-min (five days/week of moderate intensity exercise [~4.5 MET] 
for 30 minutes/day) 10. We found in our least active quintile significant cardiovascular 
benefits of 45% and 43% reduction in CVD and CVRF prevalence, respectively. Q1 
participants exercised on average 297 MET-min/week, which is equal to the effort of a 
weekly 4.8 km run at 8 km/h (~8.3 MET) or 6.4 km walk at 5.6 km/h (~4.3 MET). These 
findings reinforce previous observations that low doses of exercise can induce significant 
health effects 14, 15, 17. The high ‘return on investment’ of low exercise doses could encourage 
inactive and vulnerable populations to start exercise and gain subsequent cardiovascular 
benefits.  
 
The quest for identification of the optimal exercise dose for cardiovascular health is 
challenging, since it comprises exercise time, intensity, or a combination of both 18. The 
present study, demonstrated the lowest prevalence of CVD and CVRF between 764 to 1,091 
MET-min per week which is in agreement with the exercise recommendations of the World 
Health Organization 10. This ‘optimal’ exercise dose is a feasible goal for many individuals 
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and includes 170 to 242 min/week of moderate intensity exercise or 90 to 128 min/week of 
vigorous intensity exercise. With a reduction of 69% for CVD prevalence and 64% for CVRF 
prevalence, these exercise doses importantly contribute to primary prevention and hence the 
reduction of CVD related healthcare expenses. 
 
Interestingly, few studies revealed an upturn in mortality 11, 19 or morbidity 12 risk with higher 
doses of exercise. The exercise dose of our highest quintile (Q5) is equal to the effort of a 
weekly ~350-minute run at ~8 km/h (~8.3 MET) or a total running distance of ~47 km/week. 
Although these extreme exercisers did not report the lowest CVD or CVRF prevalence, a 57% 
reduction in CVD and 53% reduction in CVRF were found compared to non-exercisers. One 
might argue that the absence of a further decline in cardiovascular benefits at the higher 
exercise doses could relate to the amount of vigorous intensity exercise, which these 
individuals (Q5) experienced. Vigorous endurance exercise is known to induce atherosclerotic 
plaque rupture 20-22,  transient cardiac dysfunction, and cardiac remodelling 22-25. Indeed, Q5 
participants exercised significantly more (P<.001) on a vigorous intensity level (47%) 
compared to all other quintiles (Q1): 3%, Q2): 6%, Q3): 6%, Q4): 16%). However, the 
proportion of vigorous intensity exercise did not differ between CVD/CVRF and control 
participants in Q5 (CVD: 50% vs. control: 44%; P=.22, CVRF: 46% vs. control: 44%; P=.30). 
Other studies demonstrated an increased longevity of 2.8 to 6 years among elite athletes with 
high-intensity exercise compared to reference cohorts 6, 26, 27. Likewise, Gebel et al., 
demonstrated that vigorous activity was associated with a strong inverse relationship with 
mortality in the 45 and Up Study (n=204,542, aged 45 through 75) 28. Larger doses of 
vigorous exercise yielded a larger decline in (cardiovascular) mortality compared to exercise 
at a moderate intensity level alone. Although, a higher exercise dose does not yield additional 
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health benefits, it is unlikely that the amount of vigorous intensity exercise contributes to this 
finding.  
 
The present study demonstrates a curvilinear relationship between exercise and cardiovascular 
health. Hence, our findings contradict recent studies suggesting a potential U-shaped 
association 11, 12. There are several explanations for these different study outcomes. The 
results of the Copenhagen Heart Study 11 are difficult to interpret because of the low number 
of deaths (n=2) in the vigorous exercise group (n=38) 29. Furthermore, the sedentary 
(reference) group was allowed to bike or walk for a maximum of 120 min/week 11 suggesting 
the possibility that they already gained cardiovascular health benefits from these low exercise 
doses 15. Hence, the comparison between the ‘sedentary’ and vigorous exercise group is likely 
to underestimate the true exercise benefits. Within the ‘Million Women Study’ by Armstrong 
et al., the prevalence of current smokers was surprisingly higher among the daily strenuous 
exercises compared to those who did strenuous exercise between 1 and 6 times per week 
(~26% vs. ~15%). The authors acknowledge that even after adjusting for smoking, residual 
confounding may have occurred, which could explain the increased cardiovascular morbidity 
in vigorous exercisers.  
 
The main strength of our study is the extensive period of exercise history (32 [interquartile 
range Q25–Q75: 26–39] years) over which we were able to calculate the exercise dose. Other 
studies comprised shorter periods or only questioned the exercise characteristics over a single 
time point 11, 12. The primary limitation of this study is that the exercise data were entirely 
dependent on self-report. This limitation is, however, applicable to nearly all epidemiological 
studies, since virtually no studies have objectively measured lifelong exercise. Similarly, 
CVD data were obtained by questionnaires, but via cardiovascular medication usage, we 
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confirmed the CVD status of each individual. Despite our effort to correct for all potential 
confounders, it is possible that residual confounding may have occurred in the present study. 
Another caveat may be a recall bias regarding the exercise history of the participants. To 




The present study demonstrates that a regular low dose of exercise reduces cardiovascular 
morbidity, with further risk reduction at higher doses. Optimal health benefits were present 
with 170 to 242 min/week of moderate intensity exercise or 90 to 128 min/week of vigorous-
intensity exercise. CVD/CVRF prevalence did not further decrease among higher exercise 
dose groups. Therefore, our study does not confirm the recently reported U-shaped 
association between exercise and morbidity in healthy individuals, but suggests a curvilinear 
relationship between lifelong exercise patterns and cardiovascular health. 
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Figure 1. Flowchart for enrollment of the study population. 21,266 participants completed the 
online questionnaire. Initially, 5,647 participants were excluded from the study due to missing 
data (n=1,713), age below 35 years (n=3,871), diabetes type 1 (n=63). 15,619 participants 
were divided over three groups (1. CVD cases, 2. CVRF cases, and 3. Controls). We excluded 
participants with missing data for exercise history (n=938), education (n=23), smoking 
(n=569), cardiac medication usage (n=1,186), and diagnosis of CVD or CVRF below 35 years 
of age (n=463). The final study base consisted of 405 CVD cases, 1,379 CVRF cases, and 
10,656 controls.  
CVD = cardiovascular disease, CVRF = cardiovascular risk factors. 
 Figure 2. Odds ratio of cardiovascular disease and cardiovascular risk factors by subgroup. The reference group analyses includes non-
exercisers. Exercisers had a 58% lower risk to develop CVD and a 56% lower risk to develop CVRF compared to the non-exercisers. These 
associations were consistent regardless of sex, age, smoking status, family history, and level of education. The overall odds ratio (OR) was 
adjusted for: age, sex, smoking status (never, former, or current smoker), level of education (low, middle, or high education), and CVD family 
history (positive or negative).  
 Figure 3. The association between the prevalence of cardiovascular morbidity and exercise 
dose per quintile. The proportion of (A) CVD and (B) CVRF participants per exercise dose 
(MET-min/week) in quintiles. The left y-axis (bar chart) represents the proportion of 
participants in the CVD/CVRF and control groups per quintile. The right y-axis (line chart) 
represents the odds ratio with a 95% confidence interval (CI). The non-exercisers were set as 
the reference group, where the dotted line represents an odds ratio of one. During the analysis, 
we adjusted for the following potential confounders: age, sex, smoking status, level of 
education, and CVD family history.  
MET-min/week = Metabolic equivalent of task in minutes per week. 
 




Figure 4. Proportion of light, moderate, and vigorous intensity per exercise dose quintile. We 
categorized the total amount of lifelong exercise dose into light, moderate, and vigorous 
intensity, based on self-reported perceived intensity of the participant. The bars represent the 
proportion intensity per exercise dose quintile for control participants versus (A) CVD 
participants, and (B) CVRF participants. The proportion of light and moderate intensity 
exercise decreased with higher exercise dose quintiles (P<.001), whereas the proportion of 
vigorous intensity exercise increased with higher exercise dose quintiles (P<.001). 
CVD/CVRF cases performed more light intensity exercise across quintiles compared to 
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controls, whereas moderate and vigorous intensity exercise did not differ between 
CVD/CVRF cases and controls across quintiles.  
CON = controls, CVD = cardiovascular disease cases, CVRF = cardiovascular risk factor 
cases 
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n (%males) 243 (58)  1,047 (49)  1,048 (49)  1,177 (55)  1,348 (63)  1,502 (71) 
Age at study participation (years) 53±10  52±10  50±9  49±9  50±9  51±9 
Positive family history (n (%)) 203 (49)  939 (44)  879 (41)  878 (41)  926 (43)  879 (41) 
Lifelong exercise dose (MET-min/week) 0±0  297±122  623±80  924±101  1,388±181  2,909±1,336 
Cardiovascular medical history 
Age diagnosis CVD (years)* 53±10  51±10  49±9  49±9  50±9  50±9 
n total CVD cases (n (%)) 40 (10)  93 (4)  60 (3)  52 (2)  77 (4)  83 (4) 
n myocardial infarction (n (%)) 27 (6)  43 (2)  31 (1)  22 (1)  41 (2)  43 (2) 
n stroke (n (%)) 5 (1)  19 (1)  11 (1)  10 (0)  15 (1)  16 (1) 
n heart failure (n (%)) 8 (2)  31 (1)  18 (1)  20 (1)  21 (1)  24 (1) 
Level of education 
Low (n (%)) 88 (21)  225 (11)  126 (6)  133 (6)  165 (8)  146 (7) 
Intermediate (n (%)) 200 (48)  856 (40)  799 (38)  804 (38)  840 (39)  831 (39) 
High / academic (n (%)) 129 (31)  1,049 (49)  1,203 (57)  1,190 (56)  1,124 (53)  1,153 (54) 
Smoking status 
Non-smokers (n (%)) 186 (45)  1054 (49)  1137 (53)  1174 (55)  1235 (58)  1307 (61) 
Ex-smokers (n (%)) 180 (43)  950 (45)  886 (42)  846 (40)  789 (37)  713 (33) 
Smokers (n (%)) 51 (12)  126 (6)  105 (5)  107 (5)  105 (5)  110 (5) 
CVD = cardiovascular disease, MET-min/week = Metabolic equivalent of task in minutes per week. 
*CVD cases only 




Table 2. Characteristics of CVRF and control participants within the non-exercisers and exercisers quintiles of lifelong exercise dose (MET-min/week). 
Parameter 
Non-exercisers 
















n (%males) 301 (60)  1,136 (49)  1,141 (49)  1,282 (56)  1,462 (63)  1,637 (71) 
Age at study participation (years) 55±10  52±10  50±9  49±9  51±9  51±9 
Positive family history (n (%)) 242 (48)  1,047 (45)  995 (43)  969 (42)  1,019 (44)  983 (43) 
Lifelong exercise dose (MET-min/week) 0±0  290±120  616±80  919±101  1,386±184  2,918±1,331 
Cardiovascular medical history            
Age diagnosis CVRF (years)* 52±9  51±10  49±9  49±9  50±9  50±9 
n total CVRF cases (n (%)) 123 (25)  318 (14)  236 (10)  208 (9)  218 (9)  276 (12) 
n hypertension (n (%)) 92 (18)  236 (10)  169 (7)  143 (6)  154 (7)  198 (9) 
n hypercholesterolemia (n (%)) 24 (5)  69 (3)  57 (2)  56 (2)  56 (2)  68 (3) 
n diabetes type 2 (n (%)) 7 (1)  13 (1)  10 (0)  9 (0)  8 (0)  10 (0) 
Level of education 
Low (n (%)) 116 (23)  274 (12)  142 (6)  155 (7)  175 (8)  175 (8) 
Intermediate (n (%)) 225 (45)  937 (41)  881 (38)  872 (38)  918 (40)  912 (40) 
High / academic (n (%)) 159 (32)  1,095 (47)  1,284 (56)  1,281 (56)  1,214 (53)  1,220 (53) 
Smoking status 
Non-smokers (n (%)) 221 (44)  1,111 (48)  1,222 (53)  1,262 (55)  1,323 (57)  1,402 (61) 
Ex-smokers (n (%)) 224 (45)  1,053 (46)  974 (42)  930 (40)  878 (38)  791 (34) 
Smokers (n (%)) 55 (11)  142 (6)  111 (5)  116 (5)  106 (5)  114 (5) 
CVRF = cardiovascular risk factors, MET-min/week = Metabolic equivalent of task in minutes per week. 
*CVRF cases only 
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